Hardean E. Achneck
Corporate Officer/Principal chez The European Society of Cardiology
Profil
Hardean E.
Achneck is a member of several organizations including the American Heart Association, The International Society of Thrombosis & Hemostasis, The European Society of Cardiology, and the American Society of Gene & Cell Therapy.
Previously, he was the Vice President & Head-Medical Development at Dicerna Pharmaceuticals, Inc. from 2019 to 2022 and the Chief Medical Officer at Hemostemix, Inc. in 2016.
He received his undergraduate degree from Yale University and his doctorate from Yale School of Medicine.
Currently, he holds multiple positions as a member in various organizations.
Postes actifs de Hardean E. Achneck
| Sociétés | Poste | Début |
|---|---|---|
| The European Society of Cardiology | Corporate Officer/Principal | - |
| The International Society of Thrombosis & Hemostasis | Corporate Officer/Principal | - |
American Society of Gene & Cell Therapy
 American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Corporate Officer/Principal | - |
American Heart Association, Inc.
 American Heart Association, Inc. Miscellaneous Commercial ServicesCommercial Services American Heart Association, Inc. operates a voluntary health organization funded by private contributions. The organization offers services for coronary heart diseases and strokes, high blood cholesterol & physical inactivity, obesity, and diabetes. The company was founded in 1924 and is headquartered in Dallas, TX. | Corporate Officer/Principal | - |
Anciens postes connus de Hardean E. Achneck
| Sociétés | Poste | Fin |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/06/2022 |
| HEMOSTEMIX INC. | Chief Operating Officer | - |
Formation de Hardean E. Achneck
| Yale University | Undergraduate Degree |
| Yale School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HEMOSTEMIX INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
American Heart Association, Inc.
American Heart Association, Inc. Miscellaneous Commercial ServicesCommercial Services American Heart Association, Inc. operates a voluntary health organization funded by private contributions. The organization offers services for coronary heart diseases and strokes, high blood cholesterol & physical inactivity, obesity, and diabetes. The company was founded in 1924 and is headquartered in Dallas, TX. | Commercial Services |
| The International Society of Thrombosis & Hemostasis | |
| The European Society of Cardiology | |
American Society of Gene & Cell Therapy
American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Commercial Services |
